NextCure has entered a strategic partnership with Simcere Zaiming, to develop SIM0505, a new ADC targeting CDH6 for treating ...

Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the development of next-generation antibody-drug conjugates ...

There is no specific medicine for dengue yet. If ongoing Phase III trials yield positive results, an effective, affordable & ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

NextCure is joining the China biopharma gold rush, partnering with Simcere Pharmaceutical Group on development of a novel ...

Shares of NextCure, Inc. (NXTC) slumped 27% on Monday after the company announced a strategic partnership with China-based ...

ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

(Reuters) -Drug developer NextCure said on Monday it had signed a deal worth up to $745 million with China-based drugmaker Simcere Zaiming to develop a cancer therapy for solid tumors. NextCure said ...

NextCure has ramped up its antibody-drug conjugate (ADC) pivot, penning a $745 million deal for the ex-China rights to ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...